WASHINGTON--(BUSINESS WIRE)--RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion (ADME) genetic screening panel for use on next-generation sequencing (NGS) systems. The announcement was made in conjunction with the Society of Toxicology’s 50th Annual Meeting in Washington, D.C. Financial terms were not disclosed.
